DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

SA Transcripts 162.13K Followers Follow DexCom, Inc. ( DXCM ) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDT Company Participants Jereme Sylvain - Executive VP, CFO & Chief Accounting Officer Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Wells Fargo Securities, LLC, Research Division Okay. All right. Welcome back to day 2 of the 2026 Wells Fargo Healthcare Conference. I'm Larry Biegelsen, the medtech analyst. And it's my pleasure to host this fireside chat with the management from DexCom. With us, we have Jereme Sylvain, the CFO; and Joe Deltorchio from Investor Relations. So it's a fireside chat. Jereme, thanks so much for being here. Jereme Sylvain Executive VP, CFO & Chief Accounting Officer Thanks for having me. Good to be back. Question-and-Answer Session Larry Biegelsen Wells Fargo Securities, LLC, Research Division So Jereme, let's start with everyone's favorite topic, type 2 non-insulin. You presented the CONNECT data at ADA, really good results. What's the status of the publication? Jereme Sylvain Executive VP, CFO & Chief Accounting Officer Yes. And thanks for bringing up Connect. So obviously, there'll be multiple different things we will file over the course of time with CONNECT. Obviously, we're doing follow-up studies as well. As you mentioned, great results, really, really happy with it. We expect it to be published in a major journal. One of the things you cannot do is say the timing or the name of the journal, if you want it to be published in there, but we are actively working on it. And so we'd expect it to be published here in a relatively short period. Timing-wise, sometimes you have to kind of time it with the timing of the journal. So we are working closely there. But we would expect it to be in a major journal and